ARTBIO Partners with Nucleus RadioPharma to Manufacture Pb-212 Radiolabeled Therapeutic Products
Shots:
- ARTBIO and Nucleus RadioPharma have entered into a strategic manufacturing and supply agreement to manufacture former’s therapeutic product
- Under the agreement, Nucleus will utilize ARTBIO's AlphaDirect 212Pb isolation technology to manufacture 212Pb-radiolabeled therapies for P-I & P-II studies of AB001 in prostate cancer. Nucleus's facility in Rochester, Minn., will supply & manufacture ARTs for Northern & Midwest US patients
- AlphaDirect system produces highly pure 212Pb from common raw materials. Early studies of 212Pb-labeled radiopharmaceuticals demonstrated favorable results, suggesting it could meet significant clinical needs
Ref: ARTBIO | Image: ARTBIO
Related News:- Essential Pharma Acquires Reminyl (galantamine hydrobromide) Oral Capsules from Janssen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
